Pulling SEC filings + quote and writing the call…

ABEONA THERAPEUTICS INC.
Next earnings Aug 12, 2026 · consensus $-0.24 EPS, $12.5M rev
Last earnings +0.5% on 2026-05-13
Revenue grew 66.3% YoY.
Quality fundamentals and an attractive price line up (~590% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0000318306, latest 10-Q filed 2026-05-13) · EODHD · as of 6/25/2026, 8:32:24 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
ABEONA THERAPEUTICS INC. shows $5.82M in FY2025 revenue (+66.3% YoY), a 1223.1% net margin, and 44.7% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $3.00M | $1.41M | $3.50M | — | $5.82M |
| Gross profit | — | — | — | — | — |
| Operating income | -$89.8M | -$50.9M | -$47.1M | -$64.2M | -$89.4M |
| Net income | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.2M |
| Diluted EPS | — | -$5.53 | -$2.53 | -$1.55 | $1.01 |
| Net margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1072 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Last 90 days: 0 open-market buys · 11 sales
| 2026-06-16 | Vasanthavada Madhav Chief Commercial Officer | Disposed (J) | 222.00 @ $5.67 | $1.26K |
| 2026-06-15 | Silverstein Christine Berni Director | Sell | 18.2K @ $5.71 | $104K |
| 2026-06-09 | O'Malley Brendan M. SVP, Chief Legal Officer | Sell | 6.30K @ $5.30 | $33.4K |
| 2026-06-09 | Vazzano Joseph Walter Chief Financial Officer | Sell | 13.4K @ $5.30 | $71.2K |
| 2026-06-09 | Vazzano Joseph Walter Chief Financial Officer | Sell | 25.6K @ $5.39 | $138K |
| 2026-06-09 | Vasanthavada Madhav Chief Commercial Officer | Sell | 5.45K @ $5.30 | $28.9K |
| 2026-06-09 | Seshadri Vishwas Chief Executive Officer | Sell | 31.9K @ $5.30 | $169K |
| 2026-06-08 | O'Malley Brendan M. SVP, Chief Legal Officer | Sell | 4.83K @ $5.43 | $26.2K |
| 2026-06-08 | Vazzano Joseph Walter Chief Financial Officer | Sell | 10.3K @ $5.43 | $55.8K |
| 2026-06-08 | Vasanthavada Madhav Chief Commercial Officer | Sell | 4.17K @ $5.43 | $22.6K |
| 2026-06-08 | Seshadri Vishwas Chief Executive Officer | Sell | 24.4K @ $5.43 | $133K |
| 2026-05-26 | Alvino Mark Director | Gift | 500.00 |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.